. Author manuscript; available in PMC: 2007 Oct 21.

Published in final edited form as: Endocrinology. 2005 Aug 11;146(11):4887–4897. doi: 10.1210/en.2005-0572

TABLE 2.

Contractile properties of the soleus muscle (n = 7–8) in different treatment groups

	Intact + Veh	ORX + Veh	ORX + S-4 (3 mg/kg)	ORX + S-4 (10 mg/kg)	ORX + DHT (3 mg/kg)
Tetanus
P₀ (N)	0.85 ± 0.13^a	0.57 ± 0.17^b	0.86 ± 0.25^a	1.02 ± 0.17^a,^b	0.95 ± 0.21^a
P₀/CSA (kN/m²)	124 ± 27^a	83 ± 29^b	120 ± 37^a	156 ± 22^a,^b	138 ± 31^a
t_1/2R (ms)	256 ± 53	300 ± 71	286 ± 50	294 ± 74	308 ± 63
Twitch
P_t (N)	0.21 ± 0.09	0.19 ± 0.07	0.24 ± 0.07	0.28 ± 0.06^a	0.22 ± 0.05
P_t/CSA (kN/m²)	30 ± 13	28 ± 12	33 ± 11	43 ± 10^a,^b	33 ± 8
tP_t (ms)	160 ± 17	162 ± 34	161 ± 11	158 ± 18	162 ± 17
t_1/2R (ms)	222 ± 25	230 ± 72	238 ± 46	290 ± 155	237 ± 49

Data are presented as mean ± SD.

P < 0.05, compared with the vehicle-treated ORX group.

P < 0.05, compared with the intact control group.